Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 9/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30269864 | 0.91 | BTN3A1 (0.35) | BTN3A1L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL30269828 | 0.91 | BTN3A1 (0.41) | BTN3A1LMNAMEN1KMT2A | |
| SCHEMBL25012739 | 0.90 | BTN3A1 (0.35) | BTN3A1L3MBTL1MEN1KMT2ANPC1 | |
| SCHEMBL24148980 | 0.90 | MAPT (0.38) | BTN3A1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25012725 | 0.88 | BTN3A1 (0.38) | BTN3A1L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL24149229 | 0.88 | BTN3A1 (0.41) | BTN3A1L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL24149362 | 0.86 | BTN3A1 (0.34) | BTN3A1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25013459 | 0.86 | HDAC3 (0.37) | BTN3A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24149402 | 0.85 | BTN3A1 (0.36) | BTN3A1L3MBTL1MEN1KMT2ANPC1 | |
| SCHEMBL24148909 | 0.85 | BTN3A1 (0.43) | BTN3A1L3MBTL1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240287109-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-11939347-B2 | 1′-cyano nucleoside analogs and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4172160-A2 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230040586-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230040586-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021262826-A2 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287109-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | TYMP, PNP, DUT | BTN3A1 3427/4885L3MBTL1 1094/4885LMNA 437/4885 |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | TYMP, PNP, DUT | BTN3A1 3685/4885L3MBTL1 1076/4885LMNA 385/4885 |
| US-20230040586-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | TYMP, PNP, DUT | BTN3A1 3427/4885L3MBTL1 1094/4885LMNA 437/4885 |
| US-11939347-B2 | 1′-cyano nucleoside analogs and uses thereof | TYMP, PNP, DUT | BTN3A1 3685/4885L3MBTL1 1076/4885LMNA 385/4885 |
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | PNP, SLC28A1, SLC29A1 | BTN3A1 3686/4885L3MBTL1 2701/4885LMNA 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.